Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Urologix, Inc.
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
Through its latest government-linked project, Korean pharma consortium Kimco aims to speed up industry collaboration and step up technology competitiveness to move into rapidly growing pharmerging markets.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
GE Healthcare purchased Thermo Fisher’s research tools for $1 billion. Becton Dickinson acquires point-of-care diagnostic maker Alverix for $40 million. More news briefs.
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive